[{"address1": "3940 Trust Way", "city": "Hayward", "state": "CA", "zip": "94545", "country": "United States", "phone": "510 780 0819", "website": "https://benitec.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.", "fullTimeEmployees": 16, "maxAge": 86400, "priceHint": 2, "previousClose": 6.6, "open": 5.95, "dayLow": 5.742, "dayHigh": 7.17, "regularMarketPreviousClose": 6.6, "regularMarketOpen": 5.95, "regularMarketDayLow": 5.742, "regularMarketDayHigh": 7.17, "beta": 0.732, "forwardPE": -3.6402118, "volume": 381456, "regularMarketVolume": 381456, "averageVolume": 100214, "averageVolume10days": 67310, "averageDailyVolume10Day": 67310, "bid": 5.04, "ask": 8.07, "bidSize": 200, "askSize": 200, "marketCap": 64448264, "fiftyTwoWeekLow": 1.86, "fiftyTwoWeekHigh": 10.7, "priceToSalesTrailing12Months": 9206.895, "fiftyDayAverage": 7.69678, "twoHundredDayAverage": 4.63608, "currency": "USD", "enterpriseValue": 50659296, "floatShares": 6008399, "sharesOutstanding": 9367480, "sharesShort": 56144, "sharesShortPriorMonth": 12221, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.006, "heldPercentInsiders": 0.09283, "heldPercentInstitutions": 0.65704, "shortRatio": 0.28, "shortPercentOfFloat": 0.0064999997, "impliedSharesOutstanding": 9367480, "bookValue": 4.221, "priceToBook": 1.6299455, "lastFiscalYearEnd": 1688083200, "nextFiscalYearEnd": 1719705600, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -21692000, "trailingEps": -235.52, "forwardEps": -1.89, "lastSplitFactor": "1:17", "lastSplitDate": 1690329600, "enterpriseToRevenue": 7237.042, "enterpriseToEbitda": -2.366, "52WeekChange": 0.12418306, "SandP52WeekChange": 0.26238096, "lastDividendValue": 0.765, "lastDividendDate": 1527811200, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "BNTC", "underlyingSymbol": "BNTC", "shortName": "Benitec Biopharma Inc.", "longName": "Benitec Biopharma Inc.", "firstTradeDateEpochUtc": 1403616600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "b3cc27a2-16b5-3a55-8f58-57577c96b7a7", "messageBoardId": "finmb_4492928", "gmtOffSetMilliseconds": -14400000, "currentPrice": 6.88, "targetHighPrice": 30.0, "targetLowPrice": 16.0, "targetMeanPrice": 23.0, "targetMedianPrice": 23.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 14143000, "totalCashPerShare": 1.51, "ebitda": -21410000, "totalDebt": 354000, "quickRatio": 4.13, "currentRatio": 4.18, "totalRevenue": 7000, "debtToEquity": 3.078, "revenuePerShare": 0.003, "returnOnAssets": -1.15703, "returnOnEquity": -2.6758802, "freeCashflow": -11906500, "operatingCashflow": -20205000, "grossMargins": 16.42857, "operatingMargins": -3070.2856, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]